Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4651
MediciNova
MNOV
$87.6M
| $51.6K | ﹤0.01% |
39,400
-49,215
| -56% | -$67.9K |
2016 Q3
37 quarters
|
|
|
MCHPP
4652
Microchip Technology Inc 7.50% Series A Preferred Stock
MCHPP
| $51.3K | ﹤0.01% |
880
| – | – |
2025 Q1
3 quarters
|
|
|
KLRS
4653
Kalaris Therapeutics
KLRS
$64.3M
| $51.2K | ﹤0.01% |
+6,065
| New | +$38.8K |
2025 Q4
0 quarters
|
|
4654
Pampa Energía
PAM
$4.09B
| $50.6K | ﹤0.01% |
572
-778
| -58% | -$62.7K |
2025 Q2
2 quarters
|
|
4655
Myomo
MYO
$64.6M
| $50.5K | ﹤0.01% |
55,531
+11,154
| +25% | +$10.7K |
2024 Q3
5 quarters
|
|
4656
ProShares Ultra Gold
UGL
$735M
| $50.5K | ﹤0.01% |
910
-90
| -9% | -$4.71K |
2024 Q3
5 quarters
|
|
|
HEAL
4657
Global X Funds Global X HealthTech ETF
HEAL
$30.3M
| $50.3K | ﹤0.01% |
1,721
| – | – |
2023 Q2
10 quarters
|
|
4658
INmune Bio
INMB
$53.6M
| $49.9K | ﹤0.01% |
32,018
+2,012
| +7% | +$3.59K |
2024 Q2
6 quarters
|
|
4659
Bluerock Homes Trust
BHM
$32.9M
| $49.7K | ﹤0.01% |
4,658
-4
| -0.1% | -$39 |
2022 Q4
12 quarters
|
|
4660
StealthGas
GASS
$351M
| $48.9K | ﹤0.01% |
6,961
+108
| +2% | +$725 |
2025 Q2
2 quarters
|
|
4661
SES AI
SES
$328M
| $47.9K | ﹤0.01% |
26,590
+26,589
| +2,658,900% | +$59.6K |
2023 Q2
10 quarters
|
|
4662
Innovator US Equity Accelerated 9 Buffer ETF April
XBAP
$128M
| $47.2K | ﹤0.01% |
1,221
+1,168
| +2,204% | +$44.6K |
2024 Q3
5 quarters
|
|
4663
United States 12 Month Natural Gas Fund
UNL
$15.2M
| $46.9K | ﹤0.01% |
+6,360
| New | +$50.7K |
2025 Q4
0 quarters
|
|
4664
Innovator US Equity Ultra Buffer ETF November
UNOV
$107M
| $46.8K | ﹤0.01% |
1,231
-2,728
| -69% | -$103K |
2025 Q1
3 quarters
|
|
|
DHDG
4665
FT Vest U.S. Equity Quarterly 2.5 to 15 Buffer ETF
DHDG
$77.7M
| $46.1K | ﹤0.01% |
+1,356
| New | +$45.6K |
2025 Q4
0 quarters
|
|
4666
Global X Cybersecurity ETF
BUG
$2.01B
| $46K | ﹤0.01% |
+1,511
| New | +$50K |
2025 Q4
0 quarters
|
|
4667
Korea Electric Power
KEP
$14.2B
| $45.5K | ﹤0.01% |
+2,757
| New | +$43.7K |
2025 Q4
0 quarters
|
|
4668
Valhi
VHI
$422M
| $45.3K | ﹤0.01% |
3,760
+354
| +10% | +$4.72K |
2022 Q1
15 quarters
|
|
4669
CALL
Virgin Galactic
SPCE
$459M
| $45.3K | ﹤0.01% |
14,100
+100
| +0.7% | +$377 |
2025 Q2
2 quarters
|
|
4670
Black Stone Minerals
BSM
$3.1B
| $45K | ﹤0.01% |
3,388
-3,123
| -48% | -$42.2K |
2024 Q1
7 quarters
|
|
4671
Comstock Holding Companies
CHCI
$193M
| $44.6K | ﹤0.01% |
3,839
+3,125
| +438% | +$42.7K |
2025 Q3
1 quarter
|
|
|
TTAN
4672
ServiceTitan Inc
TTAN
$6.47B
| $44.2K | ﹤0.01% |
415
-39,192
| -99% | -$3.83M |
2024 Q4
4 quarters
|
|
|
SPAI
4673
Safe Pro Group Inc
SPAI
$90M
| $43.8K | ﹤0.01% |
+10,518
| New | +$57.8K |
2025 Q4
0 quarters
|
|
4674
CALL
Sanofi
SNY
$95.7B
| $43.6K | ﹤0.01% |
900
+800
| +800% | +$39.7K |
2025 Q3
1 quarter
|
|
4675
Innovator US Equity Ultra Buffer ETF March
UMAR
$144M
| $43.4K | ﹤0.01% |
1,087
-1,271
| -54% | -$50K |
2025 Q2
2 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.